About
Mimivax develops SurVaxM, a peptide immunotherapeutic vaccine designed to stimulate the immune system to target survivin-expressing cancer cells, primarily for treating glioblastoma and other cancers through immunotherapy.
Explore Mimivax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.